Orchard Therapeutics - U.S.

Orchard Therapeutics - U.S.

Biotechnology

London, United Kingdom 47,097 followers

Dedicated to transforming the lives of patients with severe and other genetic diseases through innovative gene therapy.

About us

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit www.orchard-tx.com.

Industry
Biotechnology
Company size
51-200 employees
Headquarters
London, United Kingdom
Type
Privately Held
Founded
2015
Specialties
Gene therapy, Rare diseases, and Genetic diseases

Locations

  • Primary

    245 Hammersmith Road

    3rd Floor

    London, United Kingdom W6 8PW, GB

    Get directions
  • 101 Seaport Blvd

    7th Floor

    Boston, Massachusetts 02210, US

    Get directions

Employees at Orchard Therapeutics - U.S.

Updates

Similar pages

Browse jobs